On August 18, Johnson & Johnson rose 3.15% in regular trading, trading at 268.88 USD/share, with turnover of 2.84 billion USD. Multiple positive catalysts have converged to drive the stock higher, breaking through its prior consolidation range.

On the analyst front, Guggenheim raised its target price from $270 to $287 while maintaining a Buy rating, Wells Fargo lifted its target from $272 to $282, and Argus Research elevated its target to $300. The consensus mean target now stands at approximately $277.81 according to FactSet polls, reflecting broad institutional confidence.

Pipeline momentum has further bolstered sentiment. Rybrevant Faspro secured FDA priority review for recurrent or metastatic head and neck squamous cell carcinoma, potentially becoming the first EGFR/MET-targeting subcutaneous therapy in this indication. Additionally, the company unveiled its Monarch Quest 3 robot-assisted bronchoscopy system, while strategic deals including a $2.58 billion acquisition option on Sail Biomedicines for in vivo CAR-T and the completion of the Firefly Bio acquisition reinforced its innovation pipeline. A $5.5 billion talc litigation settlement also removed a long-standing legal overhang.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)